12:21 EDT Novavax (NVAX) falls 4% to $5.76 after WSJ report on unlikely approval
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Marks’ Resignation Is a ‘Blow for Biotech Industry,’ Says RBC Analyst as Biotech Stocks Fall
- Unusually active option classes on open March 31st
- Vaccine, gene therapy makers fall after Peter Marks resignation
- U.S. to end funding for child vaccines in developing countries, NY Times reports
- Novavax call volume above normal and directionally bullish